A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo

Widespread use of gene therapy technologies is limited in part by the lack of small genetic switches with wide dynamic ranges that control transgene expression without the requirement of additional protein components 1 – 5 . In this study, we engineered a class of type III hammerhead ribozymes to develop RNA switches that are highly efficient at cis -cleaving mammalian mRNAs and showed that they can be tightly regulated by a steric-blocking antisense oligonucleotide. Our variant ribozymes enabled in vivo regulation of adeno-associated virus (AAV)-delivered transgenes, allowing dose-dependent and up to 223-fold regulation of protein expression over at least 43 weeks. To test the potential of these reversible on-switches in gene therapy for anemia of chronic kidney disease 6 , we demonstrated regulated expression of physiological levels of erythropoietin with a well-tolerated dose of the inducer oligonucleotide. These small, modular and efficient RNA switches may improve the safety and efficacy of gene therapies and broaden their use. In vivo control of expression levels of AAV-delivered genes is enabled by an engineered RNA switch.

[1]  I. Koulouridis,et al.  Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  Rosalind Kim,et al.  Capturing Hammerhead Ribozyme Structures in Action by Modulating General Base Catalysis , 2008, PLoS biology.

[3]  Ralph Weissleder,et al.  Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. , 2006, RNA.

[4]  Baoshan Zhang,et al.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges , 2015, Nature.

[5]  Sandro Bottaro,et al.  Mapping the Universe of RNA Tetraloop Folds. , 2017, Biophysical journal.

[6]  S. Haas,et al.  Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses , 2012, Nucleic acids research.

[7]  K. Fischbeck,et al.  Mifepristone-inducible transgene expression in neural progenitor cells in vitro and in vivo , 2016, Gene Therapy.

[8]  Yuanyu Huang.  Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics , 2016, Molecular therapy. Nucleic acids.

[9]  V. Rivera,et al.  Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Gao,et al.  Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.

[11]  M. Farzan,et al.  Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells , 2016, eLife.

[12]  Ron Weiss,et al.  Mammalian synthetic circuits with RNA binding proteins delivered by RNA , 2015, Nature Biotechnology.

[13]  P. Morcos,et al.  Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. , 2008, BioTechniques.

[14]  I. Macdougall,et al.  Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[15]  J. Summerton.  Morpholino antisense oligomers: the case for an RNase H-independent structural type. , 1999, Biochimica et biophysica acta.

[16]  O. Yoo,et al.  The prolonged half-lives of new erythropoietin derivatives via peptide addition. , 2006, Biochemical and biophysical research communications.

[17]  M. Salifu,et al.  Erythropoietin stimulating agents in the management of anemia of chronic kidney disease , 2008, Patient preference and adherence.

[18]  H. Bunn.  Drug-induced autoimmune red-cell aplasia. , 2002, The New England journal of medicine.

[19]  V. Rivera,et al.  Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. , 1999, Science.

[20]  R. D'Amato,et al.  Exogenous control of mammalian gene expression through modulation of RNA self-cleavage , 2004, Nature.

[21]  M. Win,et al.  A modular and extensible RNA-based gene-regulatory platform for engineering cellular function , 2007, Proceedings of the National Academy of Sciences.

[22]  Yi Zhang,et al.  Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.

[23]  R. Samulski,et al.  Autoimmune anemia in macaques following erythropoietin gene therapy. , 2004, Blood.

[24]  Michel Sadelain,et al.  Gene therapy comes of age , 2018, Science.

[25]  Martin Fussenegger,et al.  Synthetic RNA-based switches for mammalian gene expression control. , 2017, Current opinion in biotechnology.

[26]  Lucas H. Horan,et al.  The hammerhead ribozyme: structure, catalysis, and gene regulation. , 2013, Progress in molecular biology and translational science.

[27]  C. Gersbach,et al.  Mammalian Synthetic Biology: Engineering Biological Systems. , 2017, Annual review of biomedical engineering.

[28]  David H. Mathews,et al.  RNAstructure: web servers for RNA secondary structure prediction and analysis , 2013, Nucleic Acids Res..

[29]  D. Bohl,et al.  Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. , 1998, Blood.

[30]  D. Schwartz,et al.  TARGT Gene Therapy Platform for Correction of Anemia in End-Stage Renal Disease. , 2017, New England Journal of Medicine.

[31]  W. Scott,et al.  Tertiary Contacts Distant from the Active Site Prime a Ribozyme for Catalysis , 2006, Cell.

[32]  M. Farzan,et al.  Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Adamson,et al.  Erythropoietin for end-stage renal disease. , 1998, The New England journal of medicine.

[34]  Fernando Arroyo,et al.  Engineering with Biological Systems , 2011, ERCIM News.

[35]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[36]  M. Los,et al.  Selected technologies to control genes and their products for experimental and clinical purposes , 2007, Archivum Immunologiae et Therapiae Experimentalis.

[37]  R R Breaker,et al.  Rational design of allosteric ribozymes. , 1997, Chemistry & biology.

[38]  D. Bohl,et al.  Lack of an Immune Response against the Tetracycline-Dependent Transactivator Correlates with Long-Term Doxycycline-Regulated Transgene Expression in Nonhuman Primates after Intramuscular Injection of Recombinant Adeno-Associated Virus , 2002, Journal of Virology.

[39]  C. Stein,et al.  FDA-Approved Oligonucleotide Therapies in 2017. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  J. Summerton,et al.  Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. , 2007, Current topics in medicinal chemistry.

[41]  B. Suess,et al.  Conditional control of mammalian gene expression by tetracycline-dependent hammerhead ribozymes. , 2015, ACS synthetic biology.